Effects of somatostatin analog on splanchnic hemodynamics and plasma glucagon level in portal hypertensive rats

Table 1 Effects of octreotide on splanchnic hemodynamics

	Normal Cont	IHPH Cont	IHPH Thera	PHPH Cont	PHPH Thera
THBF, mL/min/100 g BW	6.30 ± 0.5	5.86 ± 0.9	4.53 ± 0.9c	2.80 ± 0.3a	2.12 ± 0.4e
THBF, mL/min/g LW	2.50 ± 0.3	1.61 ± 0.3a	1.37 ± 0.3a	1.17 ± 0.2ae	0.09 ± 0.2ae
PVI, mL/min/100 g BW	4.85 ± 0.4	7.03 ± 0.7a	5.85 ± 0.6c	7.86 ± 0.4ae	5.38 ± 0.6ca
SVR, mmHg·min/mL·100 g BW	26.68 ± 2.1	15.86 ± 2.3a	20.64 ± 2.8c	12.84 ± 1.0a	19.88 ± 2.4ca
PVR, mmHg·min/mL·100 g BW	1.72 ± 0.2	2.01 ± 0.3a	1.95 ± 0.2a	1.76 ± 0.1e	2.20 ± 0.3c
PSS, %	1.46 ± 0.3	34.29 ± 11.7a	38.77 ± 11.2a	94.4 ± 1.3ae	87.7 ± 4.5

^aP < 0.05 vs unmodeled/untreated normal controls; ^cP < 0.05 vs control group; ^eP < 0.05 vs the IHPH control group. Cont: Control; Thera: Therapy; THBF: Total hepatic blood flow; PVI: Portal venous inflow; SVR: Splanchnic vascular resistance; PVR: Portal venous resistance; PSS: Portosystemic shunt.